Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with a high risk of early relapse. The addition of carboplatin to neoadjuvant chemotherapy increases pathologic complete response (pCR) rates, which are strongly associated with survival outcomes. In the Brazilian pu...
G. Tavares, S. Ramalho, L. Silva et al.· Mastology· 0 citations
Introduction: Patients with triple-negative breast cancer (TNBC) who do not achieve pathologic complete response (pCR) after neoadjuvant chemotherapy have a worse prognosis. Adjuvant capecitabine has demonstrated benefit in selected populations, but its role after prior carboplatin exposure remains uncertain, particula...
G. Tavares, S. Ramalho, L. Silva et al.· Mastology· 0 citations
Introduction: Despite the definition of pathologic complete response (pCR) in the 8th edition of the AJCC Cancer Staging Manual as the absence of residual invasive disease after neoadjuvant chemotherapy (NAC), the prognostic significance of residual ductal carcinoma in situ (DCIS) remains uncertain.
Objective: To asse...
Augusto Ostermann Magalhães, Maria Beatriz de Paula Leite Kraft, R. Torresan et al.· Mastology· 0 citations
Introduction/Justification: Breast cancer is the most common malignancy among Brazilian women, and advanced-stage diagnosis remains frequent, partly due to limited access to organized screening and timely treatment. Although screening is nationally recommended, implementation is largely opportunistic, and its prognosti...
N. Almeida, N. S. de Azevedo, F. Brenelli et al.· Mastology· 0 citations
Introduction: Sentinel lymph node biopsy (SLNB) safety after neoadjuvant therapy in initially node-positive (cN+) breast cancer remains controversial. Additionally, evidence regarding the use of a single mapping tracer in this setting is limited.
Methods: Women with non-metastatic cT1–3 cN0–cN2 breast cancer who were...
M. B. Kraft, Arthur Chaves de Almeida, F. Brenelli et al.· Mastology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.